BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.
We and others have reported that vaccination of chronic myeloid leukaemia (CML) patients with e14a2 BCR-ABL junctional peptides can elicit moderate but transient T cell responses. To determine whether CML patients may be tolerised to BCR-ABL, here we used the same schedule to vaccinate 5 healthy subjects. Although IFN-γ and granzyme-B production, and proliferative responses to the vaccine peptides were detected in all 5 cases, responses were statistically similar to CML patients. CML patients are therefore not appreciably tolerised to BCR-ABL, and junctional peptides may only be moderately immunogenic, underlining the importance of antigen immunogenicity when designing vaccination strategies.
Rojas
José M
JM
Department of Haematology, University of Liverpool, Liverpool, UK.
Knight
Katy
K
Watmough
Sarah
S
Bell
Joanne
J
Wang
Lihui
L
Callaghan
Therese
T
Clark
Richard E
RE
D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D016022:Case-Control Studies; D049109:Cell Proliferation; D004797:Enzyme-Linked Immunosorbent Assay; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000276:immunology*; D053804:Granzymes / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000276:immunology* / Q000473:pathology*; D010446:Peptide Fragments / Q000276:immunology*; D011379:Prognosis; D013601:T-Lymphocytes / Q000276:immunology*
D019496:Cancer Vaccines; D010446:Peptide Fragments; D007371:Interferon-gamma; D016044:Fusion Proteins, bcr-abl; D053804:Granzymes